Please login to the form below

Not currently logged in
Email:
Password:

AVEO's financial head joins ImmunoGen

David Johnston appointed chief financial officer
David Johnston, Immunogen

David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role.

Johnston's switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance corporate planning and analysis at Genzyme.

Other previous roles include VP finance and chief financial officer of Genzyme Biosurgery.

In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.

“I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel Junius.

“His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the company to our next stages,” added Junius.

7th January 2014

From: Research, Sales

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics